Literature DB >> 28610781

Pilot studies of a human BCG challenge model.

Azra Blazevic1, Mei Xia1, Aldin Turan1, Janice Tennant1, Daniel F Hoft2.   

Abstract

Despite the great effort to develop an effective vaccine against tuberculosis (TB) there is currently no reliable and safe human challenge model that can be used for in vivo evaluation of new TB vaccine candidates and/or elucidation of the mechanisms of TB protective immunity. In this study, five volunteers were challenged with BCG intradermally (ID). Swab specimens were collected at multiple time points from the vaccination site pre- and post-vaccination to quantitate mycobacterial shedding as a surrogate of in vivo mycobacterial immunity. We compared the performance of the TaqMan qPCR assay against colony-forming unit cultures on 7H10 agar plates, and time to positivity (TTP) of mycobacterial growth indicator tubes (MGIT) in order to evaluate the reproducibility and sensitivity in measuring BCG burden in swab specimens. BCG was detected in swab specimens from all five volunteers by at least one method, and no single method was superior in terms of sensitivity and reproducibility. A comparison of all three methods showed significant correlations by Spearman's rank test between 7H10 agar plating and qPCR (R = 0.601, P = 0.00072), MGIT culture TTP and 7H10 agar plating (R = 0.412, P = 0.029) as well as MGIT culture TTP and qPCR (R = -0.708, P = 0.00003). However, the three methods were somewhat different with regard to early versus late detection of BCG shedding post-challenge. This ID BCG challenge model has unique potential to further explore correlations between reactogenicity and immune mechanisms involved in protection against mycobacterial infections, and could therefore become a reliable tool in the evaluation process of new TB vaccination strategies.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28610781     DOI: 10.1016/j.tube.2017.05.001

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  7 in total

Review 1.  Controlled Human Infection Models To Accelerate Vaccine Development.

Authors:  Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores
Journal:  Clin Microbiol Rev       Date:  2022-07-06       Impact factor: 50.129

Review 2.  What Have We Learnt about BCG Vaccination in the Last 20 Years?

Authors:  Hazel M Dockrell; Steven G Smith
Journal:  Front Immunol       Date:  2017-09-13       Impact factor: 7.561

3.  BCG Vaccination Induces M. avium and M. abscessus Cross-Protective Immunity.

Authors:  Getahun Abate; Fahreta Hamzabegovic; Christopher S Eickhoff; Daniel F Hoft
Journal:  Front Immunol       Date:  2019-02-19       Impact factor: 7.561

Review 4.  Harnessing donor unrestricted T-cells for new vaccines against tuberculosis.

Authors:  Simone A Joosten; Tom H M Ottenhoff; David M Lewinsohn; Daniel F Hoft; D Branch Moody; Chetan Seshadri
Journal:  Vaccine       Date:  2019-04-27       Impact factor: 3.641

5.  Sterilization by Adaptive Immunity of a Conditionally Persistent Mutant of Mycobacterium tuberculosis.

Authors:  Catherine Vilchèze; Steven A Porcelli; John Chan; William R Jacobs
Journal:  mBio       Date:  2021-01-19       Impact factor: 7.867

Review 6.  Visualizing the dynamics of tuberculosis pathology using molecular imaging.

Authors:  Alvaro A Ordonez; Elizabeth W Tucker; Carolyn J Anderson; Claire L Carter; Shashank Ganatra; Deepak Kaushal; Igor Kramnik; Philana L Lin; Cressida A Madigan; Susana Mendez; Jianghong Rao; Rada M Savic; David M Tobin; Gerhard Walzl; Robert J Wilkinson; Karen A Lacourciere; Laura E Via; Sanjay K Jain
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

7.  A CD4+ TNF+ monofunctional memory T-cell response to BCG vaccination is associated with Mycobacterium tuberculosis infection in infants exposed to HIV.

Authors:  Alex J Warr; Christine Anterasian; Javeed A Shah; Stephen C De Rosa; Felicia K Nguyen; Elizabeth Maleche-Obimbo; Lisa M Cranmer; Daniel Matemo; Jerphason Mecha; John Kinuthia; Sylvia M LaCourse; Grace C John-Stewart; Thomas R Hawn
Journal:  EBioMedicine       Date:  2022-05-06       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.